Perrigo Company Receives a Hold from RBC Capital

By Ryan Adsit

In a report released today, Randall Stanicky from RBC Capital reiterated a Hold rating on Perrigo Company (NYSE: PRGO), with a price target of $66. The company’s shares opened today at $72.59, close to its 52-week low of $65.47.

According to TipRanks.com, Stanicky is ranked 0 out of 5 stars with an average return of -8.7% and a 33.7% success rate. Stanicky covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Eagle Pharmaceuticals, and Jazz Pharmaceuticals.

Currently, the analyst consensus on Perrigo Company is Hold and the average price target is $72.50, representing a -0.1% downside.

In a report released yesterday, Jefferies also reiterated a Hold rating on the stock with a $71 price target.

The company has a one year high of $111 and a one year low of $65.47. Currently, Perrigo Company has an average volume of 2.06M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Perrigo Co. Plc engages in the production of over-the-counter consumer goods and specialty pharmaceutical products. It operates through the following segments: Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals, and Specialty Sciences. The CHC segment includes the company’s former segments, which are the Nutritionals and Israel Pharmaceuticals and Diagnostics business. The BCH segment consists of the Omega business. The Prescription Pharmaceuticals includes the Rx Pharmaceuticals business. The Specialty Sciences segment comprises of the assets, which focuses on the treatment of multiple sclerosis. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.